Terms: = Skin cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
823 results:
1. Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).
Parums DV
Med Sci Monit; 2024 May; 30():e944927. PubMed ID: 38689550
[TBL] [Abstract] [Full Text] [Related]
2. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor].
Lei JY; Li Y; Li CM; Xiong XL; Feng CC; Weng WJ; Peng XM; Zhou DH; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):445-449. PubMed ID: 38660850
[TBL] [Abstract] [Full Text] [Related]
3. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract] [Full Text] [Related]
4. Oncolytic herpes simplex virus expressing il-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract] [Full Text] [Related]
5. Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?
Fishman J; Buchbinder EI
Cancer J; 2024 Mar-Apr 01; 30(2):120-125. PubMed ID: 38527266
[TBL] [Abstract] [Full Text] [Related]
6. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
7. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Betof Warner A; Hamid O; Komanduri K; Amaria R; Butler MO; Haanen J; Nikiforow S; Puzanov I; Sarnaik A; Bishop MR; Schoenfeld AJ
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38423748
[TBL] [Abstract] [Full Text] [Related]
8. NK cells propagate T cell immunity following in situ tumor vaccination.
Jin WJ; Jagodinsky JC; Vera JM; Clark PA; Zuleger CL; Erbe AK; Ong IM; Le T; Tetreault K; Berg T; Rakhmilevich AL; Kim K; Newton MA; Albertini MR; Sondel PM; Morris ZS
Cell Rep; 2023 Dec; 42(12):113556. PubMed ID: 38096050
[TBL] [Abstract] [Full Text] [Related]
9. Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
Kim HE; Kim J; Park HK; Lee JB; Yun SJ
Melanoma Res; 2024 Feb; 34(1):38-43. PubMed ID: 37924528
[TBL] [Abstract] [Full Text] [Related]
10. Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer.
Jacover A; Zarbiv Y; Tal KH; Klein S; Breuer S; Durst R; Avni B; Grisariu S; Stepensky P; Lotem M; Maimon O; Yablonski-Peretz T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1894. PubMed ID: 37750497
[TBL] [Abstract] [Full Text] [Related]
11. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Diab A; Gogas H; Sandhu S; Long GV; Ascierto PA; Larkin J; Sznol M; Franke F; Ciuleanu TE; Pereira C; Muñoz Couselo E; Bronzon Damian F; Schenker M; Perfetti A; Lebbe C; Quéreux G; Meier F; Curti BD; Rojas C; Arriaga Y; Yang H; Zhou M; Ravimohan S; Statkevich P; Tagliaferri MA; Khushalani NI
J Clin Oncol; 2023 Oct; 41(30):4756-4767. PubMed ID: 37651676
[TBL] [Abstract] [Full Text] [Related]
12. TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm SA; Frej MS; Rafa VM; Hansen UK; Ormhøj M; Tyron A; Jensen AWP; Kadivar M; Bentzen AK; Munk KK; Aasbjerg GN; Ternander JSH; Heeke C; Tamhane T; Schmess C; Funt SA; Kjeldsen JW; Kverneland AH; Met Ö; Draghi A; Jakobsen SN; Donia M; Marie Svane I; Hadrup SR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586765
[TBL] [Abstract] [Full Text] [Related]
13. T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
[TBL] [Abstract] [Full Text] [Related]
14. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.
Ou L; Liu S; Wang H; Guo Y; Guan L; Shen L; Luo R; Elder DE; Huang AC; Karakousis G; Miura J; Mitchell T; Schuchter L; Amaravadi R; Flowers A; Mou H; Yi F; Guo W; Ko J; Chen Q; Tian B; Herlyn M; Xu X
EBioMedicine; 2023 Jun; 92():104614. PubMed ID: 37229906
[TBL] [Abstract] [Full Text] [Related]
15. Rethinking Oncologic treatment Strategies with Interleukin-2.
Ko B; Takebe N; Andrews O; Makena MR; Chen AP
Cells; 2023 May; 12(9):. PubMed ID: 37174716
[TBL] [Abstract] [Full Text] [Related]
16. Computational systems biology approach for permanent tumor elimination and normal tissue protection using negative biasing: Experimental validation in malignant melanoma as case study.
Kumari B; Sakode C; Lakshminarayanan R; Roy PK
Math Biosci Eng; 2023 Mar; 20(5):9572-9606. PubMed ID: 37161256
[TBL] [Abstract] [Full Text] [Related]
17. Natural killer cells suppress human cutaneous squamous cell carcinoma cancer cell survival and tumor growth.
Adhikary G; Heipertz EL; Preradovic M; Chen X; Xu W; Newland JJ; Kaur N; Vemuri MC; Eckert RL
Mol Carcinog; 2023 Jun; 62(6):845-854. PubMed ID: 36994661
[TBL] [Abstract] [Full Text] [Related]
18. Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.
Cui C; Chen Y; Luo Z; Zou Z; Jiang Y; Pan H; Fan Q; Zhao J; Xu Q; Jiang R; Wang X; Ma T; Guo Z; Si L; Chi Z; Sheng X; Dou Y; Tan Q; Wu D; Guo J
BMC Cancer; 2023 Feb; 23(1):121. PubMed ID: 36747118
[TBL] [Abstract] [Full Text] [Related]
19. Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma.
Gargiulo L; Ibba L; Valenti M; Costanzo A; Narcisi A
Melanoma Res; 2023 Apr; 33(2):152-154. PubMed ID: 36728879
[TBL] [Abstract] [Full Text] [Related]
20. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
[TBL] [Abstract] [Full Text] [Related]
[Next]